[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.186.91. Please contact the publisher to request reinstatement.
Article
July 1956

Clinical and Laboratory Studies of Novobiocin, a New Antibiotic

Author Affiliations

Seattle

From the Department of Medicine, University of Washington School of Medicine, and the King County Hospital.

AMA Arch Intern Med. 1956;98(1):1-7. doi:10.1001/archinte.1956.00250250007001
Abstract

Novobiocin is a new antibiotic isolated independently by three different groups of workers.1 The names given to this antibiotic, and the companies under whose supervision it was discovered, are as follows: Cathomycin (Merck); streptonivicin (Albamycin) (Upjohn); and Cardelmycin (Pfizer). Preliminary in vitro studies have shown that the antibiotic is active against the commonly encountered Gram-positive bacteria and also against certain Gram-negatives.2 Of particular importance is the fact that staphylococci resistant to other antibiotics are highly susceptible to Novobiocin. Experimental infections in animals have also indicated a high degree of activity with little toxicity.3 Laboratory studies and a clinical trial in 75 patients comprise the present report.*

Methods 

Sensitivity Tests.  —Concentrations of novobiocin causing inhibition of growth of streptococci and pneumococci were determined in tryptose phosphate broth containing 3% human blood; 0.5 ml. amounts of a 10-4 dilution of an overnight culture were added to equal amounts

×